Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20032393 | 0.91 | KCNQ3 (0.36) | P2RX3SLC6A4KCNQ3KCNQ2TRPV3 | |
| SCHEMBL17615967 | 0.85 | TAS1R3 (0.32) | TAS1R3TAS1R1P2RX3SLC6A4KCNQ3 | |
| SCHEMBL20921361 | 0.84 | TAS1R3 (0.48) | TAS1R3TAS1R1PPARGPPARA | |
| SCHEMBL21164508 | 0.83 | KDM1A (0.42) | TAS1R3TAS1R1KCNQ3KCNQ2 | |
| SCHEMBL21276094 | 0.81 | ALDH1A1 (0.41) | P2RX3KCNQ3KCNQ2TRPV3NAAA | |
| SCHEMBL22795845 | 0.81 | PDE2A (0.52) | PDE2A | |
| SCHEMBL19853074 | 0.79 | SHBG (0.39) | KCNQ2SHBG | |
| SCHEMBL22350128 | 0.78 | TAS1R3 (0.50) | TAS1R3TAS1R1 | |
| SCHEMBL22783705 | 0.77 | GRIN2B (0.36) | — | |
| SCHEMBL9945957 | 0.77 | KCNQ3 (0.39) | P2RX3KCNQ3KCNQ2TRPV3NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | TAS1R3 2452/4885TAS1R1 1374/4885P2RX3 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.